News Bad news for Sanofi as biosimilar replaces Lantus Pharmacy benefit firm axes Lantus, decision due on key combination therapy.
News Medivation in merger talks with Sanofi and others Sources say Pfizer and Celgene are also interested.
News Genzyme and AZ fall foul of UK pharma code Companies named in adverts after breaching code of practice.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.